Ray Y. Chen

Tuberculosis Research Section

NIH Main Campus, Bethesda, MD

Ray Y. Chen

Staff Clinician, Associate Research Physician

Contact: For contact information, search the NIH Enterprise Directory.

Specialty(s): Infectious Disease, Internal Medicine

  • Tuberculosis

Program Description

Clinical trials focused on diagnostics, novel treatment strategies, and treatment shortening methodologies for tuberculosis.



M.S.P.H, 2003, University of Alabama at Birmingham

M.D., 1997, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA

B.A., 1992, University of Virginia, Charlottesville, VA

Dr. Chen graduated from the Medical College of Virginia/Virginia Commonwealth University in Richmond, Virginia, then trained in Internal Medicine at the Thomas Jefferson University Hospital in Philadelphia, Pennsylvania and in Infectious Diseases at the University of Alabama at Birmingham (UAB). While at UAB, he also earned a Master of Science in Public Health with a concentration in epidemiology.

Dr. Chen came to NIAID in 2003 to the Division of AIDS (DAIDS) and was based in Beijing, China for DAIDS from 2004-2012, working with Chinese investigators. In 2012, he returned to Bethesda, MD and joined the Tuberculosis Research Section in the Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research.

Selected Publications

Chen RY, Yu X, Smith B, Liu X, Gao J, Diacon AH, Dawson R, Tameris M, Zhu H, Qu Y, Zhang R, Pan S, Jin X, Goldfeder LC, Cai Y, Arora K, Wang J, Vincent J, Malherbe ST, Thienemann F, Wilkinson RJ, Walzl G, Barry CE 3rd. Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis. Lancet Microbe. 2021 Oct;2(10):e518-e526.

Xie YL, de Jager VR, Chen RY, Dodd LE, Paripati P, Via LE, Follmann D, Wang J, Lumbard K, Lahouar S, Malherbe ST, Andrews J, Yu X, Goldfeder LC, Cai Y, Arora K, Loxton AG, Vanker N, Duvenhage M, Winter J, Song T, Walzl G, Diacon AH, Barry CE 3rd. Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Sci Transl Med. 2021 Feb 3;13(579):eabd7618.

Lee A, Xie YL, Barry CE, Chen RY. Current and future treatments for tuberculosis. BMJ. 2020 Mar 2;368:m216.

Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, Yuan X, Mo X, Zhu H, Xu P, Gao Q, Lee M, Lee J, Smith LE, Chen RY, Joh JS, Cho Y, Liu X, Ruan X, Liang L, Dharan N, Cho SN, Barry CE 3rd, Ellner JJ, Dorman SE, Alland D. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 2017 Sep 14;377(11):1043-1054.

Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY, Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE 3rd, Winter J, Walzl G; Catalysis TB–Biomarker Consortium, Lucas L, Spuy GV, Stanley K, Thiart L, Smith B, Du Plessis N, Beltran CG, Maasdorp E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Koegelenberg C, Vorster M, Griffith-Richards S. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med. 2016 Oct;22(10):1094-1100.

Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park SK, Cho SN, Barry CE 3rd. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med. 2014 Dec 3;6(265):265ra166.

Visit PubMed for a complete publication listing.

Content last reviewed on